Clinical Therapeutics 2011-01-01

Iloperidone for the Management of Adults with Schizophrenia

Brian L. Crabtree, John Montgomery, Brian L. Crabtree, John Montgomery

Index: Clin. Ther. 33(3) , 330-45, (2011)

Full Text: HTML

Abstract

Background Iloperidone is a second-generation antipsychotic drug approved in May 2009 by the US Food and Drug Administration (FDA) for the acute treatment of schizophrenia in adults. It is a piperidinyl-benzisoxazole derivative with mixed serotonin (5HT2A) and D2 dopamine antagonist properties.

Related Compounds

  • Iloperidone

Related Articles:

A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.

2013-02-01

[J. Clin. Psychopharmacol. 33(1) , 3-10, (2013)]

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.

2013-02-01

[CNS Spectr. 18(1) , 43-54, (2013)]

Stable-isotope dilution LC-MS/MS assay for determination of iloperidone and its two major metabolites, P 88 and P 95, in human plasma: application to a bioequivalence study.

2013-03-01

[Bioanalysis 5(6) , 669-86, (2013)]

Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms.

2013-12-01

[CNS Spectr. 18(6) , 285-8, (2013)]

Iloperidone: A new drug for the treatment of schizophrenia.

2011-02-15

[Am. J. Health Syst. Pharm. 68(4) , 301-8, (2011)]

More Articles...